Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients
- 10 March 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (8), 1191-1196
- https://doi.org/10.1200/jco.2008.18.3285
Abstract
Purpose: This study was conducted to characterize the effect of food on the relative bioavailability of lapatinib.Patients and Methods: A single 1,500-mg, oral dose of lapatinib was administered to 27 patients with advanced solid tumors on each of three occasions that were 1 week apart, in random order: after an overnight fast, with a low-fat breakfast, and with a high-fat breakfast.Results: The low-fat breakfast produced mean increases in lapatinib area under the concentration-time curve (AUC) of 167% (2.67-fold) and maximum concentration (Cmax) of 142% (2.42-fold). The high-fat breakfast produced mean increases in lapatinib AUC of 325% (4.25-fold) and Cmaxof 203% (3.03-fold) compared with the fasted state. Increased bioavailability in the fed state did not significantly decrease relative variability. Therefore, absolute variability in systemic exposure was increased.Conclusion: These large increases in lapatinib bioavailability and absolute variability support the recommendation for dosing in the fasted state to achieve consistent therapeutic exposure. Prescribers and patients should consider the potential consequences of toxicity or diminished efficacy that might result from dosing without regard to variations in diet.Keywords
This publication has 22 references indexed in Scilit:
- The Role of Efflux and Uptake Transporters inN-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug InteractionsDrug Metabolism and Disposition, 2008
- Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based ModellingClinical Pharmacokinetics, 2006
- Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy RegimenClinical Cancer Research, 2005
- Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic CarcinomasJournal of Clinical Oncology, 2005
- Single-Dose Clinical Pharmacokinetic Studies of GefitinibClinical Pharmacokinetics, 2005
- Increasing throughput of parallel on‐line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug developmentRapid Communications in Mass Spectrometry, 2004
- Effects of Food on the Clinical Pharmacokinetics of Anticancer AgentsClinical Pharmacokinetics, 2004
- 558 The effect of food on the pharmacokinetics of GW572016European Journal of Cancer Supplements, 2003
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987